Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Fennec Pharmaceuticals (FENC) over the last 12 years, with Q3 2025 value amounting to -$75000.0.

  • Fennec Pharmaceuticals' Change in Account Payables rose 8706.9% to -$75000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 11587.47%. This contributed to the annual value of -$537000.0 for FY2024, which is 13868.88% down from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Change in Account Payables of -$75000.0 as of Q3 2025, which was up 8706.9% from $661000.0 recorded in Q2 2025.
  • Fennec Pharmaceuticals' Change in Account Payables' 5-year high stood at $2.0 million during Q1 2025, with a 5-year trough of -$1.8 million in Q2 2021.
  • Its 5-year average for Change in Account Payables is $210125.0, with a median of $252500.0 in 2022.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Change in Account Payables skyrocketed by 138730.16% in 2021, and later plummeted by 140517.24% in 2024.
  • Fennec Pharmaceuticals' Change in Account Payables (Quarter) stood at $477000.0 in 2021, then tumbled by 130.19% to -$144000.0 in 2022, then soared by 681.25% to $837000.0 in 2023, then tumbled by 174.79% to -$626000.0 in 2024, then soared by 88.02% to -$75000.0 in 2025.
  • Its Change in Account Payables was -$75000.0 in Q3 2025, compared to $661000.0 in Q2 2025 and $2.0 million in Q1 2025.